Get started
Author

Christoph Daniel Friedli

Observed names: C Friedli, C. Friedli, Christoph Friedli, Christoph, Friedli, Friedli, Christoph, Friedli, Christoph Daniel
ORCID: 0000-0001-7974-5432
Observed ORCID: 0000-0001-7974-5432
OpenAlex ID: A5015572113
Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome
2023 · Christine Lebrun-Frénay, Aksel Siva, et al. · JAMA Neurology · 95
PDF
Automatic detection of lesion load change in Multiple Sclerosis using convolutional neural networks with segmentation confidence
2019 · Richard McKinley, Rik Wepfer, et al. · NeuroImage Clinical · 74
PDF
Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course
2019 · Greta Zoehner, Andrei Miclea, et al. · Therapeutic Advances in Neurological Disorders · 45
PDF
Vaccine Hesitancy in Patients With Multiple Sclerosis
2021 · Lara Diem, Christoph Friedli, et al. · Neurology Neuroimmunology & Neuroinflammation · 31
PDF
Multidimensional phenotyping of the post‐COVID ‐19 syndrome: A Swiss survey study
2022 · Lara Diem, Anina Schwarzwald, et al. · CNS Neuroscience & Therapeutics · 28
PDF
Fatigue in Post-COVID-19 Syndrome: Clinical Phenomenology, Comorbidities and Association With Initial Course of COVID-19
2022 · Lara Diem, Livia Fregolente-Gomes, et al. · Journal of Central Nervous System Disease · 28
PDF
Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
2019 · Myriam Briner, Maud Bagnoud, et al. · Therapeutic Advances in Neurological Disorders · 27
PDF
Reliable brain morphometry from contrast‐enhanced T1w‐MRI in patients with multiple sclerosis
2022 · Michael Rebsamen, Richard McKinley, et al. · Human Brain Mapping · 23
PDF
Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS)
2022 · H Hammer, N Kamber, et al. · Multiple Sclerosis and Related Disorders · 16
Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers
2024 · L Diem, A Ovchinnikov, et al. · Multiple Sclerosis and Related Disorders · 14
PDF
Anti‐kelchlike protein 11 antibody‐associated encephalitis: Two case reports and review of the literature
2023 · Alejandro León Betancourt, Anina Schwarzwald, et al. · European Journal of Neurology · 12
PDF
Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients
2022 · Christoph Friedli, Franca Wagner, et al. · Multiple Sclerosis Journal · 12
Multiple sclerosis as a model to investigate SARS‐CoV ‐2 effect on brain atrophy
2022 · Michael Rebsamen, Christoph Friedli, et al. · CNS Neuroscience & Therapeutics · 10
PDF
Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study
2021 · Panagiotis Chaloulos-Iakovidis, Franca Wagner, et al. · Therapeutic Advances in Neurological Disorders · 10
Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort
2020 · Krenar Veselaj, Nicole Kamber, et al. · CNS Neuroscience & Therapeutics · 10
PDF
Recommendations for the Treatment of Multiple Sclerosis in Family Planning, Pregnancy and Lactation in Switzerland: Immunotherapy
2024 · Michael Graber, Alice Panchaud, et al. · Clinical and Translational Neuroscience · 8
PDF
Sex differences in multiple sclerosis relapse presentation and outcome: a retrospective, monocentric study of 134 relapse events
2024 · Pauline Thränhardt, Admirim Veselaj, et al. · Therapeutic Advances in Neurological Disorders · 8
PDF
Anti‐neurochondrin antibody as a biomarker in primary autoimmune cerebellar ataxia—a case report and review of the literature
2022 · Anina Schwarzwald, Anke Salmen, et al. · European Journal of Neurology · 8
Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature
2021 · L. Diem, R. Hoepner, et al. · Journal of Neuroimmunology · 7
PDF
Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study
2024 · Christoph Friedli, Nik Krajnc, et al. · Journal of Central Nervous System Disease · 6
PDF
Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies
2021 · Christoph Friedli, Lara Diem, et al. · Therapeutic Advances in Neurological Disorders · 6
Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022
2022 · Christoph Friedli, Anke Salmen, et al. · Clinical and Translational Neuroscience · 4
PDF
Hypogammaglobulinemia: A contributing factor to multiple sclerosis fatigue?
2022 · L. Diem, M.E. Evangelopoulos, et al. · Multiple Sclerosis and Related Disorders · 4
PDF
Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
2022 · Helly Hammer, Robert Hoepner, et al. · Vaccines · 4
PDF
Application of the “risk of ambulatory disability” (RoAD) score in a “real‐world” single‐center multiple sclerosis cohort
2022 · Maximilian Pistor, Helly Hammer, et al. · CNS Neuroscience & Therapeutics · 2
PDF
Works count: 59
Citation count: 496
H-index: 12
I10-index: 15
Year
Topic
Type